EA202191239A1 - Соединения и их применение для лечения дефицита 1-антитрипсина - Google Patents

Соединения и их применение для лечения дефицита 1-антитрипсина

Info

Publication number
EA202191239A1
EA202191239A1 EA202191239A EA202191239A EA202191239A1 EA 202191239 A1 EA202191239 A1 EA 202191239A1 EA 202191239 A EA202191239 A EA 202191239A EA 202191239 A EA202191239 A EA 202191239A EA 202191239 A1 EA202191239 A1 EA 202191239A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
deficiency
antitripsin
compounds
application
Prior art date
Application number
EA202191239A
Other languages
English (en)
Inventor
Найджел Рамсден
Дэвид Джон Фокс
Джеймс Эндрю Хантингтон
Original Assignee
З Фактор Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by З Фактор Лимитед filed Critical З Фактор Лимитед
Publication of EA202191239A1 publication Critical patent/EA202191239A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к производным оксопиримидинилметилбензамида, например, в форме фармацевтически приемлемой соли или кристаллической формы, фармацевтическим композициям, содержащим указанные производные, и их медицинскому применению, в частности для лечения недостаточности 1-антитрипсина (A1AD или AATD).
EA202191239A 2018-12-14 2019-12-13 Соединения и их применение для лечения дефицита 1-антитрипсина EA202191239A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1820450.3A GB201820450D0 (en) 2018-12-14 2018-12-14 Compound and its use for the treatment of alpha1-antitryspin deficiency
PCT/GB2019/053552 WO2020120992A1 (en) 2018-12-14 2019-12-13 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Publications (1)

Publication Number Publication Date
EA202191239A1 true EA202191239A1 (ru) 2021-09-21

Family

ID=65147137

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191239A EA202191239A1 (ru) 2018-12-14 2019-12-13 Соединения и их применение для лечения дефицита 1-антитрипсина

Country Status (21)

Country Link
US (2) US11312689B2 (ru)
EP (1) EP3894393B8 (ru)
JP (1) JP7487203B2 (ru)
KR (1) KR20210104080A (ru)
CN (1) CN113227057A (ru)
AU (1) AU2019398520A1 (ru)
BR (1) BR112021011477A2 (ru)
CA (1) CA3122658A1 (ru)
CO (1) CO2021009083A2 (ru)
CR (1) CR20210376A (ru)
EA (1) EA202191239A1 (ru)
EC (1) ECSP21051825A (ru)
GB (1) GB201820450D0 (ru)
IL (1) IL283938A (ru)
MA (1) MA54456A (ru)
MX (1) MX2021006884A (ru)
NI (1) NI202100047A (ru)
PE (1) PE20211789A1 (ru)
SG (1) SG11202105878WA (ru)
WO (1) WO2020120992A1 (ru)
ZA (1) ZA202103977B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820450D0 (en) * 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
GB201918404D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB202009074D0 (en) * 2020-06-15 2020-07-29 Z Factor Ltd Compound
GB202009069D0 (en) * 2020-06-15 2020-07-29 Z Factor Ltd Process
GB202108544D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108543D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108542D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
WO2022263829A1 (en) * 2021-06-16 2022-12-22 Z Factor Limited COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052034A2 (en) * 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
EP1250129A2 (en) * 2000-01-20 2002-10-23 Washington University METHODS TO TREAT $g(a)-1-ANTITRYPSIN DEFICIENCY
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
JP5319113B2 (ja) * 2004-03-26 2013-10-16 メチルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害剤
EP1832586A1 (en) * 2006-03-10 2007-09-12 Oridis Biomed Forschungs- und Entwicklungs GmbH Thiazole-piperidine derivatives in treatment of diseases of liver and the pancreas
EP2114141A2 (en) 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
CN101224207A (zh) * 2007-10-12 2008-07-23 中国科学院上海有机化学研究所 具有诱导自吞噬治疗错误折叠蛋白聚集所致疾病的药物及其筛选方法
BRPI0821027B8 (pt) * 2007-12-20 2021-05-25 Bayer Ip Gmbh 4-(4-ciano-2-tioaril)di-hidropirimidinonas para tratamento e/ou prevenção de lesões do pulmão e do sistema cardiovascular, seu processo de preparação e seu uso, e medicamento
KR20140083058A (ko) * 2011-11-08 2014-07-03 아레나 파마슈티칼스, 인크. G 단백질-커플링된 Mas 수용체의 조절제 및 그와 관련된 장애의 치료
MX2014005715A (es) * 2011-11-11 2014-05-28 Pfizer N-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]- benzamida para el tratamiento de leucemia mielogenosa cronica.
US20140221335A1 (en) * 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2016031987A1 (ja) * 2014-08-29 2016-03-03 国立大学法人東京大学 オートタキシン阻害活性を有するピリミジノン誘導体
GB201820450D0 (en) 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
GB201918413D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918414D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918404D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB202009069D0 (en) * 2020-06-15 2020-07-29 Z Factor Ltd Process
GB2612007A (en) * 2021-06-15 2023-04-26 Z Factor Ltd Compounds
WO2022263829A1 (en) * 2021-06-16 2022-12-22 Z Factor Limited COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Also Published As

Publication number Publication date
US20210332015A1 (en) 2021-10-28
AU2019398520A1 (en) 2021-07-01
US11312689B2 (en) 2022-04-26
JP2022515372A (ja) 2022-02-18
NI202100047A (es) 2021-08-31
KR20210104080A (ko) 2021-08-24
MA54456A (fr) 2022-03-23
US20220274932A1 (en) 2022-09-01
CO2021009083A2 (es) 2021-07-30
WO2020120992A1 (en) 2020-06-18
BR112021011477A2 (pt) 2021-08-31
EP3894393A1 (en) 2021-10-20
EP3894393B8 (en) 2023-02-15
SG11202105878WA (en) 2021-07-29
PE20211789A1 (es) 2021-09-09
ECSP21051825A (es) 2021-11-18
GB201820450D0 (en) 2019-01-30
ZA202103977B (en) 2022-10-26
MX2021006884A (es) 2021-09-14
EP3894393B1 (en) 2022-12-21
CA3122658A1 (en) 2020-06-18
JP7487203B2 (ja) 2024-05-20
CR20210376A (es) 2021-10-18
IL283938A (en) 2021-07-29
CN113227057A (zh) 2021-08-06

Similar Documents

Publication Publication Date Title
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
MX2021004431A (es) Procesos novedosos.
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
JOP20190086A1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения
EA202190151A1 (ru) Фармацевтическая комбинация для применения при возрастных и/или дегенеративных заболеваниях
EA201890412A1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ
PH12017501668A1 (en) Bace1 inhibitors
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.
EA202091169A1 (ru) Применяемые в качестве ингибиторов iap миметики smac и их применение
PL424452A1 (pl) Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
MX2022006180A (es) Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.